AbbVie vs Johnson & Johnson: Founders, CEOs and History
AbbVie was founded in 2013 by Abbott Laboratories (spin-off origin) and is led by Robert A. Michael. Johnson & Johnson was founded in 1886 by Robert Wood Johnson, James Wood Johnson, Edward Mead Johnson and is led by Joaquin Duato.
Company facts
AbbVie
- Founded
- 2013
- Headquarters
- North Chicago, Illinois
- Current CEO
- Robert A. Michael
- Employees
- 57,000
Johnson & Johnson
- Founded
- 1886
- Headquarters
- New Brunswick, New Jersey
- Current CEO
- Joaquin Duato
- Employees
- 140,800
Founders
AbbVie
Abbott Laboratories (spin-off origin)
Abbott Laboratories was AbbVie's corporate predecessor. AbbVie's official launch materials describe the company as formed in 2013 following separation from Abbott. Richard A.
Johnson & Johnson
Robert Wood Johnson
Robert Wood Johnson (1845-1910) co-founded Johnson & Johnson in 1886 and served as its first president.
James Wood Johnson
James Wood Johnson (1856-1932) co-founded Johnson & Johnson with his brothers and focused on manufacturing. After Robert's death in 1910 he became president, leading the company until 1932.
Edward Mead Johnson
Edward Mead Johnson (1852-1934) co-founded Johnson & Johnson in 1886. He left J&J in 1897 and later founded Mead Johnson & Company, known for infant nutrition products.
CEOs and their tenures
AbbVie
- Richard A. Gonzalez2013–2024
Founding Chairman and Chief Executive Officer
Served as AbbVie's chief executive officer from its formation in 2013 through June 2024 and as executive chairman through June 2025.
Source - Robert A. Michael2024–present
Chairman and Chief Executive Officer
Became chief executive officer on July 1, 2024 and chairman on July 1, 2025. He previously led finance, commercial operations, and corporate strategy roles at AbbVie.
Source
Johnson & Johnson
- Ralph Larsen1989–2002
Former Chairman and Chief Executive Officer
Larsen's acquisitions, including Neutrogena, Cordis, DePuy, and Centocor, broadened J&J into medical devices and biologics, laying groundwork for today's MedTech segment and immunology franchise.
Source - William Weldon2002–2012
Former Chairman and Chief Executive Officer
Weldon's later years were overshadowed by a wave of consumer product recalls, including Tylenol and Motrin, tied to manufacturing-quality problems.
Source - Alex Gorsky2012–2022
Former Chairman and Chief Executive Officer
Gorsky's tenure set up the 2023 Kenvue separation completed under his successor and saw J&J's single-dose COVID-19 vaccine authorized in 2021. He also oversaw the $30 billion Actelion acquisition in 2017 and the early years of talc litigation.
Source - Joaquin Duato2022–present
Chairman and Chief Executive Officer
Under Duato, J&J's sales reached $94.193 billion in FY2025 with $26.804 billion in net earnings, and the company guides to its first $100 billion year in 2026. He also launched the DePuy Synthes separation and the 2026 talc settlement proposal.
Source
Timeline: AbbVie and Johnson & Johnson side by side
1886Johnson & Johnson
Johnson & Johnson Founded
Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson found the company in New Brunswick, New Jersey, with 14 employees, to mass-produce sterile surgical dressings after Robert was inspired by antiseptic pioneer Joseph Lister's 1885 warnings about i…
1920Johnson & Johnson
Band-Aid Brand Adhesive Bandages Introduced
J&J introduces the first mass-produced adhesive bandage, sold under the Band-Aid brand starting in 1921; it becomes one of the most recognized consumer-health brands in the world before J&J later spins its consumer division out as Kenvue in 2023.
1943Johnson & Johnson
Robert Wood Johnson II Writes 'Our Credo'
Chairman Robert Wood Johnson II authors 'Our Credo,' a one-page statement ranking the company's responsibilities to customers, employees, communities, and shareholders in that order; it remains J&J's official governing philosophy and was later cited as the bas…
1944Johnson & Johnson
J&J Goes Public
Johnson & Johnson lists publicly, becoming an independent, market-traded company as it expands into a diversified healthcare business under Chairman Robert Wood Johnson II.
1982Johnson & Johnson
Tylenol Cyanide Poisonings and Nationwide Recall
After seven people in the Chicago area die from cyanide-laced Extra-Strength Tylenol capsules, J&J issues a nationwide recall of 31 million bottles within a week -- far beyond what investigators said was necessary -- citing Our Credo's customer-safety priority…
2012Johnson & Johnson
Alex Gorsky Becomes CEO
Gorsky succeeds William Weldon as CEO amid a period of manufacturing-quality recalls, and spends the next decade restoring J&J's operational reputation while expanding the pharmaceutical and MedTech businesses and developing a single-dose COVID-19 vaccine duri…
2013AbbVie
AbbVie Launches as an Independent Company
AbbVie launched after Abbott Laboratories separated its research-based pharmaceutical business and began NYSE trading under ABBV.
2015AbbVie
Pharmacyclics Acquisition Completed
AbbVie completed its acquisition of Pharmacyclics, adding Imbruvica and expanding its hematologic oncology business.
2019AbbVie
Skyrizi Receives Initial U.S. Approval
The FDA approved Skyrizi for adults with moderate to severe plaque psoriasis in April 2019.
2019AbbVie
Rinvoq Receives Initial U.S. Approval
The FDA approved Rinvoq for adults with moderate to severe rheumatoid arthritis in August 2019.
2020AbbVie
Allergan Acquisition Completed
AbbVie completed the Allergan acquisition, adding neuroscience, eye care, and Allergan Aesthetics products including Botox and Juvederm.
2022Johnson & Johnson
Joaquin Duato Becomes CEO
Duato becomes CEO in January 2022, later adding the chairman title, and begins preparing the separation of J&J's consumer-health business from its medicine and device operations.
2023AbbVie
U.S. Humira Biosimilar Competition Begins
Humira began facing U.S. biosimilar competition, and AbbVie reported a subsequent decline in Humira revenue.
2023Johnson & Johnson
Kenvue Separation
J&J completes the spinoff of its consumer-health business (Band-Aid, Tylenol, Listerine, Neutrogena) as the standalone public company Kenvue, narrowing J&J around its higher-margin Innovative Medicine and MedTech segments.
2024AbbVie
ImmunoGen Acquisition Completed
AbbVie completed its acquisition of ImmunoGen, adding Elahere and antibody-drug conjugate programs.
2024AbbVie
Robert A. Michael Becomes CEO
Robert A. Michael succeeded Richard A. Gonzalez as chief executive officer effective July 1, 2024.
2024AbbVie
Cerevel Therapeutics Acquisition Completed
AbbVie completed its acquisition of Cerevel Therapeutics, adding clinical-stage neuroscience programs.
2025AbbVie
Robert A. Michael Becomes Chairman
Robert A. Michael added the chairman role effective July 1, 2025, when Richard A. Gonzalez retired from the board.
2025AbbVie
FY2025 Revenue Reaches $61.160 Billion
AbbVie reported FY2025 net revenue of $61.160 billion and net income of $4.226 billion.
2025Johnson & Johnson
FY2025 Sales of $94.193B
Johnson & Johnson reports $94.193 billion in sales and $26.804 billion in net earnings, split roughly 64% Innovative Medicine and 36% MedTech, both segments growing about 6% year over year.
2025Johnson & Johnson
Orthopaedics Separation Announced
In October 2025 J&J announced plans to separate its orthopaedics business as a standalone company operating as DePuy Synthes, targeting completion in 2027.
2026AbbVie
Q1 2026 Revenue Reaches $15.002 Billion
AbbVie reported first-quarter 2026 net revenue of $15.002 billion, up 12.4 percent on a reported basis.
2026Johnson & Johnson
Proposed Talc Resolution and Raised Guidance
J&J raised 2026 sales guidance to about $101.1 billion after Q2 sales of $25.31 billion, and on July 27, 2026 proposed an estimated $5.5 billion resolution of remaining ovarian talc claims.
Acquisitions
AbbVie
- ImmunoGen, Inc.2024$10.1B
- Cerevel Therapeutics2024$8.7B
- Allergan plc2020$63B
- Pharmacyclics, Inc.2015$21B
Johnson & Johnson
- Intra-Cellular Therapies2025$14.6B
- Shockwave Medical2024$13.1B
- Kenvue separation2023Undisclosed
- Abiomed2022$16.6B
- Actelion2017$30B
Questions about AbbVie vs Johnson & Johnson
Who is the CEO of AbbVie Inc. and Johnson & Johnson?
AbbVie Inc. is led by Robert A. Michael and Johnson & Johnson is led by Joaquin Duato. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was AbbVie Inc. founded vs Johnson & Johnson?
Johnson & Johnson was founded in 1886 — 127 years before AbbVie Inc., which was founded in 2013. Johnson & Johnson's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger AbbVie Inc..
How many employees does AbbVie Inc. have compared to Johnson & Johnson?
AbbVie Inc. employs approximately 57,000 people, while Johnson & Johnson employs approximately 140,800. Johnson & Johnson has the larger workforce at 140,800 employees, compared to AbbVie Inc.'s 57,000. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are AbbVie Inc. and Johnson & Johnson headquartered?
Both AbbVie Inc. and Johnson & Johnson are headquartered in United States, meaning they operate under the same primary regulatory and tax environment.
Who founded AbbVie Inc. and Johnson & Johnson?
AbbVie Inc. was founded by Abbott Laboratories (spin-off origin). Johnson & Johnson was founded by Robert Wood Johnson, James Wood Johnson, Edward Mead Johnson.
Which company has a longer operating history — AbbVie Inc. or Johnson & Johnson?
Johnson & Johnson has been operating for approximately 140 years, making it the more established of the two companies. AbbVie Inc. has been in operation for around 13 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the AbbVie vs Johnson & Johnson overview